TRAIL Monoclonal antibody
TRAIL Monoclonal Antibody for WB, IHC, ELISA
Host / Isotype
Mouse / IgG1
Reactivity
Human and More (1)
Applications
WB, IF, IHC, ELISA
Conjugate
Unconjugated
CloneNo.
1B9B4
Cat no : 66756-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | human milk tissue |
Positive IHC detected in | human tonsillitis tissue, human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 1 publications below |
IF | See 1 publications below |
Product Information
66756-1-Ig targets TRAIL in WB, IF, IHC, ELISA applications and shows reactivity with Human samples.
Tested Reactivity | Human |
Cited Reactivity | human |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Immunogen | TRAIL fusion protein Ag25746 |
Full Name | tumor necrosis factor (ligand) superfamily, member 10 |
Calculated Molecular Weight | 281 aa, 33 kDa |
Observed Molecular Weight | 28-30 kDa |
GenBank Accession Number | BC032722 |
Gene Symbol | TRAIL |
Gene ID (NCBI) | 8743 |
RRID | AB_2882102 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for TRAIL antibody 66756-1-Ig | Download protocol |
IHC protocol for TRAIL antibody 66756-1-Ig | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Adv Healthc Mater TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582). | ||
Cancers (Basel) Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. | ||
Front Bioeng Biotechnol The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma |